Mandate

VINGE ADVISES ON OPUS GROUP’S RIGHTS ISSUE

Vinge is advising Opus Group in connection with a rights issue of approximately SEK 150 million. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 10 March 2015. The board of directors will determine the terms and conditions governing the rights issue not later five days prior to the record day. A prospectus is expected to be published on 11 March 2015 and the subscription period is 17-31 March 2015.

Vinge’s team advising on the preparation of the prospectus and capital markets issues consists of responsible partner Anders Strid together with associates Daniel Lennartsson, Frida Bäckgren and Anna Hofling Johansson (tax).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026